Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized double-blind placebo-controlled study of obeticholic acid (DSP-1747) in nonalcoholic steatohepatitis
jRCT2080221948Phase 2
- Sponsor
- Sumitomo Pharma
- Start
- Oct 2012
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in metabolic dysfunction-associated steatohepatitis (MASH) comparing DSP-1747 (obeticholic acid) with Placebo (2 arms).
02
Drugs
obeticholic acid
03
Conditions
metabolic dysfunction-associated steatohepatitis (MASH)
Beyond the preview
Go deeper on jRCT2080221948.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080221948.